Characteristics Of Patients Achieving Complete Or Partial Response (Cr/Pr) With Tazemetostat (Taz) In Wild‐Type Relapsed/Refractory (R/R) Follicular Lymphoma (Fl)
dc.contributor.author | Batlevi, C. L. | |
dc.contributor.author | Salles, G. | |
dc.contributor.author | Tilly, H. | |
dc.contributor.author | Chaidos, A. | |
dc.contributor.author | McKay, P. | |
dc.contributor.author | Phillips, T. | |
dc.contributor.author | Assouline, S. | |
dc.contributor.author | Campbell, P. | |
dc.contributor.author | Ribrag, V. | |
dc.contributor.author | Damaj, G. Laurent | |
dc.contributor.author | Dickinson, M. | |
dc.contributor.author | Jurczak, W. | |
dc.contributor.author | Kaźmierczak, M. | |
dc.contributor.author | Opat, S. | |
dc.contributor.author | Radford, J. R. | |
dc.contributor.author | Schmitt, A. | |
dc.contributor.author | Rajarethinam, A. | |
dc.contributor.author | Shang, G. | |
dc.contributor.author | Morschhauser, F. | |
dc.date.accessioned | 2021-07-01T20:14:47Z | |
dc.date.available | 2022-07-01 16:14:46 | en |
dc.date.available | 2021-07-01T20:14:47Z | |
dc.date.issued | 2021-06 | |
dc.identifier.citation | Batlevi, C. L.; Salles, G.; Tilly, H.; Chaidos, A.; McKay, P.; Phillips, T.; Assouline, S.; Campbell, P.; Ribrag, V.; Damaj, G. Laurent; Dickinson, M.; Jurczak, W.; Kaźmierczak, M. ; Opat, S.; Radford, J. R.; Schmitt, A.; Rajarethinam, A.; Shang, G.; Morschhauser, F. (2021). "Characteristics Of Patients Achieving Complete Or Partial Response (Cr/Pr) With Tazemetostat (Taz) In Wild‐Type Relapsed/Refractory (R/R) Follicular Lymphoma (Fl)." Hematological Oncology 39: n/a-n/a. | |
dc.identifier.issn | 0278-0232 | |
dc.identifier.issn | 1099-1069 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/168382 | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.title | Characteristics Of Patients Achieving Complete Or Partial Response (Cr/Pr) With Tazemetostat (Taz) In Wild‐Type Relapsed/Refractory (R/R) Follicular Lymphoma (Fl) | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | |
dc.subject.hlbsecondlevel | Otolaryngology | |
dc.subject.hlbsecondlevel | Neurosciences | |
dc.subject.hlbsecondlevel | Obstetrics and Gynecology | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbsecondlevel | Ophthalmology | |
dc.subject.hlbsecondlevel | Public Health | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/168382/1/hon21_2880.pdf | |
dc.identifier.doi | 10.1002/hon.21_2880 | |
dc.identifier.source | Hematological Oncology | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.